


Albania

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



International units Factor VIII 0.46 ▲ 0.48 ▲ 1.56 per capita Factor IX 0.14 ▼ 0.02 ▲ 0.14 Organisation Comprehensive Care Centres (CCC's) No No No ▲ Yes of care Haemophilia Treatment Centres Yes Yes Yes Yes National Haemophilia Council or Co-ordinating Group Yes Yes Yes Number of groups in decision-making on haemophilia care 0 ▲ 2 ▲ 3 Number of groups choosing haemophilia treatment products 0 ▲ 2 2 National Tender for procurement of factor concentrates Yes Yes Yes Treatment Home Treatment No No No regimens % of people with haemophilia using home treatment <10% <10% <10% Treatment delivered to the patient's home No No No No	* * * * * * * * * * * * * * * * * * *	1.57 0.14 Yes No
Organisation No Pes Organisation No	•	Yes No
of care Haemophilia Treatment Centres National Haemophilia Council or Co-ordinating Group Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates Treatment Home Treatment Home Treatment Wo of people with haemophilia using home treatment Yes Yes Yes Yes Yes Yes Yes Yes Yes Ye		No
National Haemophilia Council or Co-ordinating Group Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates Treatment Home Treatment Home Treatment Wo of people with haemophilia using home treatment No <10% Yes Yes Yes Yes Yes Yes Yes Ye		
Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates Treatment Home Treatment Home Treatment Wo of people with haemophilia using home treatment No No No No <10%	V	No
Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates Treatment Home Treatment Home Treatment Wo of people with haemophilia using home treatment No No No No <10%		
National Tender for procurement of factor concentrates Yes Yes Yes Yes Yes Yes Yes Yes Treatment Home Treatment No No No regimens % of people with haemophilia using home treatment <10% <10% <10%		3
Treatment Home Treatment No No No regimens % of people with haemophilia using home treatment <10% <10% <10%		2
regimens % of people with haemophilia using home treatment <10% <10% <10%		Yes
	A	Yes
Treatment delivered to the national's home		<10%
realment derivered to the patient shortle		No
Prophylaxis treatment availability No No No		No
Children currently on prophy (%) 0 0		0
Adults currently on prophy (%) 0 0		0
Access to ITI (% of people with inhibitors) 0 0		0
Access to Emergency medicine and acute surgery Sometimes Sometimes		Sometimes
specialist services Paediatrics Sometimes \(\sqrt{Yes} \)		Yes
Infectious disease specialists (especially HIV) Never Yes		Yes
Hepatology Sometimes ▲ Yes		Yes
Rheumatology Never Sometimes		Sometimes
Orthopaedics Sometimes \(\struct \) Yes	_	Never
Physiotherapy Sometimes \(\Delta \) Yes	_	Sometimes
Dentistry Sometimes ▼ Never	A	Yes
Obstetrics and Gynaecology Never Sometimes		Sometimes
Genetics Never Never		Never
Social and psychological support Yes Value Sometimes		Sometimes
Pain management Never Sometimes		Sometimes
General surgery Sometimes Sometimes		Sometimes
Urology Sometimes ▲ Yes	_	Sometimes
Share of Expected Haemophilia A 88% ▼ 46%	A	65%
Bleeding Disorder Haemophilia B 30% ▲ 43% ▼ 21%	A	37%
Prevalence von Willebrand Disease 0% 0%	_	0%
Haemophilia Pasma-derived factor concentrate Always ▼ Never △ Always		Always
replacement Recombinant factor concentrate Rarely Rarely Rarely		Rarely
therapy Plasma Rarely Rarely Rarely		Rarely
		Rarely
Cryoprecipitate Always Always Always Always		Rarely
Cryoprecipitate Always Always ▲ Rarely VWD replacement Plasma-derived factor concentrate Never ▲ Rarely		
VWD replacement Plasma-derived factor concentrate Never A Rarely	A	Always
VWD replacement Plasma-derived factor concentrate Never A Rarely	A	Always Rarely